The company is currently scaling its peptide production capacity, aiming for a monthly output of 800,000 vials by early autumn. With gross margins projected between 60% and 80%, the firm is positioning itself within the sports medicine market to address supply shortages for pharma-grade, cGMP-manufactured peptides. Management points to recent industry consolidation, such as the acquisition of PolyPeptide Group AG, as evidence of the high demand for licensed manufacturing capacity.
Vector Science & Therapeutics Targets August Revenue After Going Public
Following its April reverse takeover, Vector Science & Therapeutics has filed its inaugural quarterly financial report, signaling a transition toward commercial operations. The Mequon-based firm expects to begin generating revenue from its peptide manufacturing division in August, while advancing its lead pain management technology toward federal regulatory approval.
Simultaneously, the development of VectorMist, a device for perioperative pain management in laparoscopic surgery, remains on schedule. The company intends to submit a 510(k) filing to the FDA, with potential revenue generation targeted before the close of 2026. To support these commercial launches, the firm has assembled a specialized sales team focused on orthopedic and sports medicine distribution channels. Leadership will outline these growth strategies during an inaugural investor Q&A session scheduled for July 28.
Comments (0)
No comments yet. Be the first!